Trial Profile
A Cancer Research UK Phase I Trial of IMA950 (A Novel Multi-Peptide Vaccine) Plus GM-CSF in Patients With Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs IMA 950 (Primary) ; Sargramostim; Temozolomide
- Indications Astrocytoma; Glioblastoma
- Focus Adverse reactions; First in man; Pharmacodynamics
- 25 May 2016 Primary endpoint has been met. (Total number of patients showing patient-individual T-cell responses against a single or multiple tumor-associated peptides (TUMAP) contained in the study vaccine IMA950 at one or more post-vaccination time points by HLA multimer analysis), as per results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 25 May 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 04 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.